Latest research on LEA29Y

Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. It differs from abatacept (Orencia) by only 2 amino acids. FDA approved on June 15, 2011.

LEA29Y side effects

The LEA-tg pigs generated in this study express high levels of LEA29Y, specifically in the β-cells, with no signs of β-cell dysfunction or systemic immunosuppression, such as increased susceptibility to opportunistic infections. [source, 2012]
Therefore, a modification of this antibody was undertaken, with substitution of two amino acids within the B7.2 binding domain, creating a second generation of CTLA4-Ig (LEA29Y), which was shown to have higher affinity to both B7.1 and B7.2, translating into a 10-fold increase in biological potency. [source, 2011]
A second-generation version of this molecule (LEA29Y), with two amino acid mutations, has been developed to have increased binding avidity for CD86 [2]. [source, 2005]
One patient treated with LEA29Y withdrew because of a viral upper respiratory tract infection. [source, 2005]